Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins
about
Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?Engineering humoral immunity as prophylaxis or therapyMechanisms of RNA-induced toxicity in CAG repeat disordersIntrabodies as neuroprotective therapeuticsUse of Genetically Altered Stem Cells for the Treatment of Huntington's Disease.Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.A huntingtin peptide inhibits polyQ-huntingtin associated defectsRandom mutagenesis of BoNT/E Hc nanobody to construct a secondary phage-display library.IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's diseaseGγ recruitment systems specifically select PPI and affinity-enhanced candidate proteins that interact with membrane protein targetsTranslational research in Huntington's disease: opening up for disease modifying treatmentDominant protein interactions that influence the pathogenesis of conformational diseases.Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1.Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapyExperimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.Polyglutamine (PolyQ) diseases: genetics to treatments.Recombinant Antibody Fragments for Neurodegenerative Diseases.Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process.Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression.Evaluating the current state of the art of Huntington disease research: a scientometric analysis.In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
P2860
Q26738467-045DE3B3-2AD6-44B6-AA1D-32577472E367Q26800101-4473997F-7B07-48DF-BC2D-D21737926CCCQ26860030-968D6B92-DF53-4950-8C7C-39BD1F3FDB95Q27003896-8DB8CDDE-6076-4E70-A075-215A9EF04241Q33788929-DCECA1F9-BFBF-4589-B235-205BEAB9D23EQ34109060-DF2FC2DA-97A6-4DAE-BB7B-176AAC852D8BQ34117333-08620ED3-9FD3-4F30-9494-18291B69F9FBQ34313192-F5E741FF-615D-4EB0-8D0D-E18462BC8C17Q34828144-BCE2CB27-0CBC-4DB4-830B-E571FB8C73CDQ35157493-6A608A0A-AA01-4711-AD98-489F62536C23Q35992493-52025074-F1D9-4798-ABE1-35C9EEA2A489Q36142398-BFBEFF17-B1CB-4FE4-A52A-7ECE385DE261Q36297830-8A53098A-8691-4915-80DD-293ABA44EE1BQ36722683-137A9810-8EE9-4006-977F-CCF27329381CQ36966865-8071CC60-DA91-4381-9B40-B0AD568F16C3Q37052361-48D1EA81-60C2-465D-BEAC-DD52D2F326B0Q37280507-973C560D-5DCF-4A25-BD31-701584739B97Q38108756-8AF20E33-252C-46DC-8D5A-415946E99496Q38139218-51179FAE-421D-4EE4-A15D-178FE5C4EA20Q38210865-11F663ED-D9F5-40FE-B8D2-B42A6644A1E2Q38970823-16D0FA2B-4C93-4707-BBF1-48B8B03DD3F4Q39112084-0B5A86B2-71C2-4D84-A40B-C682AD64DAF4Q39289367-E4E28E30-456B-42AC-8478-621F4D6D2634Q41518158-4B5610F0-22B9-4DDF-ABB6-3F1F30775C43Q50015412-61CAC1DC-74DF-48FC-89FE-1094FA69AC01Q56568322-8FD5F1E0-4C1F-4F56-A686-83BA8E271E7F
P2860
Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Engineered antibody therapies ...... d toxic intracellular proteins
@en
Engineered antibody therapies ...... toxic intracellular proteins.
@nl
type
label
Engineered antibody therapies ...... d toxic intracellular proteins
@en
Engineered antibody therapies ...... toxic intracellular proteins.
@nl
prefLabel
Engineered antibody therapies ...... d toxic intracellular proteins
@en
Engineered antibody therapies ...... toxic intracellular proteins.
@nl
P2093
P2860
P1476
Engineered antibody therapies ...... d toxic intracellular proteins
@en
P2093
Anne Messer
David C Butler
Julie A McLear
P2860
P304
P356
10.1016/J.PNEUROBIO.2011.11.004
P577
2011-11-18T00:00:00Z